OBP2A Antibody Market Size, Share, and Industry Analysis, By Class (Polyclonal and Monoclonal), By Host (Rabbit, Mouse, and Others), By Conjugate (Unconjugated and Conjugated), By Application (Immunohistochemistry (IHC), Enzyme-linked Immunosorbent Assay (ELISA), Western Blotting (WB), and Others), By End-user (Research Laboratories, Pharmaceutical & Biotechnology Companies, and Others), and Regional Forecast, 2025-2032

The OBP2A antibody market is witnessing significant growth due to several key factors such as the increase in research and development initiatives, particularly in the molecular biology and immunology, increasing prevalence of olfactory-related disorders, such as anosmia and hyposmia. This is coupled with the expansion of the biomedical and pharmaceutical industries focused on the development of therapies targeting these disorders. Such factors are increasing the need for OBP2A antibodies in clinical research and applications.

• For instance, according to the Journal of Experimental Medicine in December 2022, a study indicated that tumor-derived OBP2A enhances the growth of prostate cancer and promotes castration resistance by facilitating the infiltration of myeloid-derived suppressor cells (MDSCs) into the tumor microenvironment. Knocking down OBP2A significantly inhibits the development of castration-resistant prostate cancer (CRPC) and improves the efficacy of immunotherapies such as CTLA-4 and PD-1 antibodies, suggesting its potential as a therapeutic target in cancer treatment.

OBP2A Antibody Market Driver

Expanding Research Applications of OBP2A Antibody Boosts Market Growth

The OBP2A antibody is a useful tool for researchers studying odorant-binding proteins. Odorant-binding proteins are involved in the initial stages of olfaction by binding to odorant molecules and transporting them to olfactory receptors. Researchers are leveraging OBP2A antibodies in various assays such as ELISA, IHC, and Western Blots to detect and quantify OBP2A protein expression, which is expected to boost its utilization, driving the market growth.

• For instance, as of July 2023, the product anti-OBP2A antibody (AA 16-170) is used in research applications such as ELISA and IHC.

Request a Free sample to learn more about this report.

In cancer research, antibodies against OBP2A are used to analyze its expression in tumor tissues, aiding in understanding its role in cancer biology and potential therapeutic targets. The U.S. accounted for an estimated 1,958,310 cancer cases in 2023, witnessing a growth of 2.1% compared to 2022.

OBP2A Antibody Market Restraint

Compromised Results Due to Improper Sample Handling May Hinder Market Growth

The effectiveness of OBP2A antibodies can be compromised by improper sample handling, which could lead to inaccurate results in assays such as ELISA. Moreover, the performance of OBP2A antibodies in various applications such as western blotting and immunohistochemistry requires the careful optimization of working dilutions and conditions, which can pose challenges for researchers, hindering the market growth.

• For instance, according to the antibodies-online in July 2024, fresh samples are recommended for use to prevent protein degradation and denaturation.

OBP2A Antibody Market Opportunity

Technological Advancements for Antibody Production

Improvements in antibody production technologies are facilitating the development of OBP2A antibodies, making them more accessible for research and clinical applications. This is particularly relevant in the fields of molecular biology and immunology, where understanding protein functions is crucial. Such advancements are expected to propel the market expansion in the near future.

• For instance, according to an article published by BIOMATIK in November 2023, the evolution of recombinant antibody technologies has transformed the landscape of antibody production. Techniques such as hybridoma generation, deep sequencing, and protein display technologies have improved the specificity and yield of antibodies, including OBP2A.

Key Insights

The report covers the following key insights:

• Key Industry Developments (Mergers, Acquisitions, and Partnerships)


• Guidelines for the Use of Antibodies in Research


• Technological Advancements in the OBP2A Antibody Market


• Impact of COVID-19 on the Market

Segmentation

Analysis by Class

Based on class, the market is divided into polyclonal and monoclonal.

The monoclonal antibody segment is expected to hold a substantial share of the global market. This growth can be attributed to the rising preference for monoclonal antibodies in research applications, as it requires high specificity and reproducibility that monoclonal antibody offers. Furthermore, these antibodies are particularly suited for quantitative assays and applications where precise detection is necessary. Such advantages are expected to boost the segment growth over the coming years.

• For instance, an article published on ScienceDirect in 2021 stated that monoclonal antibodies are an excellent choice for protein detection tools, including quantitative ELISA, required to produce consistent and standardized data.

Analysis by Host

By host, the market is divided into rabbit, mouse, and others.

The rabbit segment accounted for a significant share of the OBP2A antibody market. The OBP2A antibodies available in the market are mostly obtained from the rabbit host. This is mainly due to the advantageous characteristics such as a greater immune response, higher yield of antibody-producing cells, enhanced sensitivity in applications, and greater genetic diversity, which make rabbits an ideal host for producing antibodies such as OBP2A. This is anticipated to fuel the segment growth.

• For instance, as of July 2023, Thermo Fisher Scientific Inc. offers the Invitrogen OBP2A Polyclonal Antibody for IHC, which is obtained from the rabbit.

Analysis by Conjugate

By conjugate, the market is categorized into unconjugated and conjugated.

The unconjugated segment held a major share of the OBP2A antibody market in 2023. The growth can be attributed to the greater advantages of unconjugated antibodies over conjugated antibodies, such as the flexibility in labeling, reduction of background signals, and others. Such advantages are expected to boost the preference for these antibodies, driving the segment growth in the coming years.

• For instance, as of July 2024, antibodies-online mentioned that unconjugated antibodies allow researchers to choose the specific fluorescent dye or enzyme for detection, which can be tailored to the experimental setup. This is particularly useful for experiments requiring multiple labels or specific detection methods.

Analysis by Application

By application, the market is segmented into immunohistochemistry (IHC), enzyme-linked immunosorbent assay (ELISA), western blotting (WB), and others.

The immunohistochemistry (IHC) segment accounted for a considerable share of the market in 2023. The growth is due to the predominant use of the OBP2A antibody for IHC applications to detect and localize the OBP2A protein in tissue samples, as this technique allows for the assessment of the protein's expression and distribution within the cellular context of the tissue. As a result, several prominent players are offering the OBP2A antibody globally for IHC applications, which is anticipated to spur segment growth.

• For instance, as of July 2024, Biorbyt Ltd provides OBP2A antibody for the immunohistochemistry (IHC) application.

Analysis by End-user

By end-user, the market is categorized into pharmaceutical & biotechnology companies, research laboratories, and others.

The research laboratories segment accounted for a major share of the OBP2A antibody market in 2023. The segment growth is due to the significant focus of these laboratories on the use of OBP2A antibodies in cancer research and other conditions. Moreover, the OBP2A antibodies available in the market are restricted for use for research purposes only, which is anticipated to boost the penetration in research laboratories, driving the segment growth.

• For instance, as of July 2024, Biorbyt Ltd’s OBP2A antibody for the IHC and ELISA is preferred for research use only and restricted in clinical applications.

Regional Analysis

To gain extensive insights into the market, Request for Customization

Based on region, the market has been studied across North America, Asia Pacific, Europe, Latin America, and the Middle East & Africa.

North America accounted for the largest share of the global OBP2A antibody market in 2023. The growth of the market in the region is attributed to the rise of chronic diseases such as cancer, cardiovascular diseases, and diabetes, which is increasing the demand for ELISA tests. These tests are essential for diagnosing and monitoring such conditions, leading to a higher volume of tests being conducted in research settings. Moreover, these tests involve the use of OBP2A antibodies for research purposes, which is expected to boost the regional market growth.

• For instance, in January 2023, the National Center for Biotechnology Information (NCBI) reported that 1,958,310 new cancer cases were projected to occur in the U.S.

Europe is the second-largest market based on the demand for OBP2A antibodies. The regional growth can be attributed to the key focus of companies offering these products for various research purposes and clinical applications.

• For instance, as of July 2024, Proteintech Group, Inc. offers OBP2A Polyclonal antibody for its application in ELISA in the U.K. and Germany.

Asia Pacific is expected to grow substantially over the forthcoming years. The region’s growth can be attributed to the expanding number of pharmaceutical & biotechnology companies, contributing to the increased research and development activities. Such a scenario is anticipated to boost the utilization of OBP2A antibody in the region.

Key Players Covered

The global market is fragmented, with a large number of companies offering various OBP2A antibody products.

The report includes the profiles of the following key players:

• Thermo Fisher Scientific Inc. (U.S.)


• OriGene Technologies, Inc. (U.S.)


• Atlas Antibodies (Sweden)


• Novus Biologicals (U.S.)


• Biomatik (Canada)


• Boster Biological Technology (U.S.)


• EpigenTek Group Inc. (U.S.)


• Enzo Biochem Inc. (U.S.)


• Proteintech Group, Inc. (U.S.)

Key Industry Developments

• In January 2023, Quantum-Si and Aviva Systems Biology Corporation partnered to co-develop sample preparation kits for the protein sequencing. This is expected to lead to a higher demand for OBP2A antibodies as researchers delve deeper into the roles of specific proteins in biological processes and diseases.


• In November 2021, Aviva Systems Biology Corporation joined the YCharOS Industry Advisory Committee (IAC) to evaluate commercially available antibody reagents better to deal with the inconsistent antibody performance, which is a significant challenge for researchers.